CS264317B2 - Process for preparing pharmaceutical agent - Google Patents
Process for preparing pharmaceutical agent Download PDFInfo
- Publication number
- CS264317B2 CS264317B2 CS843099A CS309984A CS264317B2 CS 264317 B2 CS264317 B2 CS 264317B2 CS 843099 A CS843099 A CS 843099A CS 309984 A CS309984 A CS 309984A CS 264317 B2 CS264317 B2 CS 264317B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- layer
- adhesive
- active substance
- container
- layers
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 239000010410 layer Substances 0.000 claims abstract description 148
- 239000013543 active substance Substances 0.000 claims abstract description 59
- 239000012790 adhesive layer Substances 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 13
- 229940127557 pharmaceutical product Drugs 0.000 claims abstract description 13
- 229920000642 polymer Polymers 0.000 claims abstract description 9
- 238000013270 controlled release Methods 0.000 claims abstract description 8
- 239000011159 matrix material Substances 0.000 claims abstract description 5
- 239000000853 adhesive Substances 0.000 claims description 32
- 239000002904 solvent Substances 0.000 claims description 30
- 239000004480 active ingredient Substances 0.000 claims description 29
- 239000011241 protective layer Substances 0.000 claims description 19
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 6
- 239000002270 dispersing agent Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000010030 laminating Methods 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 230000001070 adhesive effect Effects 0.000 description 23
- 239000007787 solid Substances 0.000 description 18
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 17
- 239000000006 Nitroglycerin Substances 0.000 description 17
- 229920002367 Polyisobutene Polymers 0.000 description 17
- 229960003711 glyceryl trinitrate Drugs 0.000 description 17
- 239000000463 material Substances 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 12
- 229920005989 resin Polymers 0.000 description 12
- 239000011347 resin Substances 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 9
- 239000013032 Hydrocarbon resin Substances 0.000 description 8
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 8
- 229920006270 hydrocarbon resin Polymers 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 229920005987 OPPANOL® Polymers 0.000 description 7
- 229960000330 bupranolol Drugs 0.000 description 7
- -1 polyethylene Polymers 0.000 description 7
- DMBSFYPSHNCYAR-RJMJUYIDSA-N 1,3-dinitrooxypropan-2-yl nitrate (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O DMBSFYPSHNCYAR-RJMJUYIDSA-N 0.000 description 6
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 6
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 6
- 229920006271 aliphatic hydrocarbon resin Polymers 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 229920006272 aromatic hydrocarbon resin Polymers 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 6
- 229960001722 verapamil Drugs 0.000 description 6
- 229910002012 Aerosil® Inorganic materials 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000011229 interlayer Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229960001673 diethyltoluamide Drugs 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 229920005601 base polymer Polymers 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 238000005375 photometry Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- SEMAIQRIDIHYEZ-UHFFFAOYSA-N 2-propan-2-ylpentanenitrile Chemical compound CCCC(C#N)C(C)C SEMAIQRIDIHYEZ-UHFFFAOYSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002402 Oppanol® B 100 Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000948 sympatholitic effect Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3315272A DE3315272C2 (de) | 1983-04-27 | 1983-04-27 | Pharmazeutisches Produkt und Verfahren zu seiner Herstellung |
| DE19833315245 DE3315245A1 (de) | 1983-04-27 | 1983-04-27 | Pharmazeutisches produkt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS309984A2 CS309984A2 (en) | 1988-09-16 |
| CS264317B2 true CS264317B2 (en) | 1989-07-12 |
Family
ID=25810346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS843099A CS264317B2 (en) | 1983-04-27 | 1984-04-26 | Process for preparing pharmaceutical agent |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0144486B1 (en]) |
| AU (1) | AU560710B2 (en]) |
| CA (1) | CA1239318A (en]) |
| CS (1) | CS264317B2 (en]) |
| DE (1) | DE3485306D1 (en]) |
| DK (1) | DK159413C (en]) |
| ES (1) | ES8704740A1 (en]) |
| FI (1) | FI80604C (en]) |
| GR (1) | GR79183B (en]) |
| HU (1) | HU195735B (en]) |
| IE (1) | IE57367B1 (en]) |
| NZ (1) | NZ207796A (en]) |
| PL (1) | PL145261B1 (en]) |
| YU (1) | YU45615B (en]) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3347278A1 (de) * | 1983-12-28 | 1985-07-11 | Bayer Ag, 5090 Leverkusen | Wirkstoffabgabesysteme |
| US4532244A (en) * | 1984-09-06 | 1985-07-30 | Innes Margaret N | Method of treating migraine headaches |
| EP0186019B1 (de) * | 1984-12-22 | 1993-10-06 | Schwarz Pharma Ag | Wirkstoffpflaster |
| EP0262753A1 (en) * | 1986-09-30 | 1988-04-06 | Paco Research Corporation | Scopolamine transdermal delivery system |
| DE3743947A1 (de) * | 1987-09-01 | 1989-03-09 | Lohmann Gmbh & Co Kg | Vorrichtung zur gesteuerten abgabe von nicotin, verfahren zu ihrer herstellung sowie ihre verwendung |
| DE3743946A1 (de) * | 1987-09-01 | 1989-03-09 | Lohmann Gmbh & Co Kg | Vorrichtung zur abgabe von nitroglycerin an die haut, verfahren zu ihrer herstellung sowie ihre verwendung |
| DE3743945A1 (de) * | 1987-09-01 | 1989-03-09 | Lohmann Gmbh & Co Kg | Vorrichtung zur abgabe von stoffen, verfahren zu ihrer herstellung sowie ihre verwendung |
| CA2028256A1 (en) * | 1989-10-23 | 1991-04-24 | Bahram Farhadieh | Multiple layer transdermal drug administration system |
| AU653156B2 (en) * | 1990-06-14 | 1994-09-22 | Dermamed | Transdermal administration to humans and animals |
| CA2078961A1 (en) * | 1992-04-21 | 1993-10-22 | John Wick | Two-hand pouch patch application |
| DE4224325C1 (de) * | 1992-07-23 | 1994-02-10 | Sanol Arznei Schwarz Gmbh | Wirkstoffpflaster für niedrigschmelzende und/oder flüchtige Wirkstoffe und Verfahren zu seiner Herstellung |
| DE4301783C1 (de) * | 1993-01-23 | 1994-02-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil |
| DE4305881C1 (de) * | 1993-02-26 | 1994-03-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung |
| DE4406332C1 (de) * | 1994-02-28 | 1995-06-22 | Sanol Arznei Schwarz Gmbh | Pharmazeutische Verwendung von Nitroglycerin zur Verhinderung unerwünschter Wehentätigkeit bei Säugern in einer transdermalen Applikationsform |
| US5906830A (en) * | 1995-09-08 | 1999-05-25 | Cygnus, Inc. | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) * | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| DE2920500A1 (de) * | 1979-05-21 | 1980-11-27 | Boehringer Sohn Ingelheim | Pharmazeutische zubereitung in form eines polyacrylatfilmes |
| JPS5770816A (en) * | 1980-10-17 | 1982-05-01 | Ono Pharmaceut Co Ltd | Multilayered film preparation of prostagladin of prolonged action |
-
1984
- 1984-04-03 AU AU26382/84A patent/AU560710B2/en not_active Expired
- 1984-04-03 CA CA000451200A patent/CA1239318A/en not_active Expired
- 1984-04-03 GR GR74298A patent/GR79183B/el unknown
- 1984-04-04 EP EP84103695A patent/EP0144486B1/en not_active Expired - Lifetime
- 1984-04-04 DE DE8484103695T patent/DE3485306D1/de not_active Expired - Lifetime
- 1984-04-11 NZ NZ207796A patent/NZ207796A/en unknown
- 1984-04-26 HU HU841624A patent/HU195735B/hu unknown
- 1984-04-26 ES ES531930A patent/ES8704740A1/es not_active Expired
- 1984-04-26 CS CS843099A patent/CS264317B2/cs unknown
- 1984-04-26 DK DK208784A patent/DK159413C/da not_active IP Right Cessation
- 1984-04-26 FI FI841663A patent/FI80604C/fi not_active IP Right Cessation
- 1984-04-27 IE IE1055/84A patent/IE57367B1/en not_active IP Right Cessation
- 1984-04-27 PL PL1984247440A patent/PL145261B1/pl unknown
- 1984-04-27 YU YU76184A patent/YU45615B/sh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUT37355A (en) | 1985-12-28 |
| ES8704740A1 (es) | 1987-04-16 |
| FI80604B (fi) | 1990-03-30 |
| CS309984A2 (en) | 1988-09-16 |
| DK208784D0 (da) | 1984-04-26 |
| EP0144486B1 (en) | 1991-11-27 |
| FI841663A7 (fi) | 1984-10-28 |
| DE3485306D1 (de) | 1992-01-09 |
| AU2638284A (en) | 1984-11-01 |
| IE57367B1 (en) | 1992-08-12 |
| PL145261B1 (en) | 1988-08-31 |
| IE841055L (en) | 1984-10-27 |
| FI841663A0 (fi) | 1984-04-26 |
| EP0144486A3 (en) | 1986-05-14 |
| PL247440A1 (en) | 1985-03-26 |
| NZ207796A (en) | 1987-07-31 |
| YU45615B (sh) | 1992-07-20 |
| GR79183B (en]) | 1984-10-02 |
| DK159413B (da) | 1990-10-15 |
| EP0144486A2 (en) | 1985-06-19 |
| CA1239318A (en) | 1988-07-19 |
| FI80604C (fi) | 1990-07-10 |
| AU560710B2 (en) | 1987-04-16 |
| YU76184A (en) | 1988-04-30 |
| DK159413C (da) | 1991-03-18 |
| HU195735B (en) | 1988-07-28 |
| DK208784A (da) | 1984-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4769028A (en) | Pharmaceutical product, in medical bandage form | |
| US5494680A (en) | Transdermal delivery device | |
| US6893655B2 (en) | Transdermal delivery devices | |
| CS264317B2 (en) | Process for preparing pharmaceutical agent | |
| CA1312800C (en) | Transdermal therapeutic system, its use and process for the production thereof | |
| PT89706B (pt) | Metodo e dispositivo para a impressao de farmacos de libertacao transdermico | |
| EP1386605A1 (en) | Improved transdermal delivery system for the administration of rotigotine | |
| HRP931308A2 (en) | Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for the preparation thereof | |
| KR20010052806A (ko) | 개별 층으로 구성된 적층물 제조 방법 | |
| EP1386604A1 (en) | Improved transdermal delivery system | |
| JPH0316571A (ja) | 段階的な薬物放出を呈する皮膚経由医療薬 | |
| JPS6123165B2 (en]) | ||
| NZ298428A (en) | Transdermal system to dispense (s)-3-methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol or salt thereof | |
| SI8410761A8 (sl) | Postopek za izdelavo obliža za nadzorovano transdermalno doziranje aktivnih substanc | |
| SK277842B6 (en) | Therapeutic system for aplication of effective matters on skin method of its manufacture and its using | |
| AU2013242824A1 (en) | Transdermal therapeutic system for administration of fentanyl or an analog thereof |